Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. SPY
7. RXST
8. SPGI
9. RIVN
10. BFH

Go back to Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
(NASDAQ: IMUX) Delayed: 15.46 +0.60 (4.04%)
Previous Close $14.86    52 Week High $ 
Open $14.88    52 Week Low $ 
Day High $15.68    P/E N/A 
Day Low $14.47    EPS $ 
Volume 62,763